Evidence map›Paper›PMID 42583378›Full record

ArticleFrontiers in medicine2026

Resolved HBV infection is an independent risk factor for enhanced systemic inflammatory responses in COVID-19 patients.

Yifan Xu, Jia Lu, Wei Chen, Xiaoxiang Yan, Weiguo Hu, Xiaogang Xiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yifan Xu *Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jia Lu *Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wei Chen *Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoxiang YanDepartment of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weiguo HuMedical Center on Aging of Ruijin Hospital, Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaogang XiangDepartment of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the systemic inflammatory responses and outcomes in coronavirus disease 2019 (COVID-19) patients with resolved hepatitis B virus (HBV) infection or non-HBV infection. Methods: This single-center, retrospective study was conducted in Tongji Hospital of Wuhan, China, from 20 January 2020 to 30 March 2020. A total of 215 COVID-19 cases with available test results were included. Demographic and clinical characteristics, and results of laboratory test results, were collected and analyzed. Results: Of the 215 included patients, the numbers of patients with current HBV infection, resolved HBV infection, and non-HBV infection were 15, 134, and 66, respectively. Inflammatory biomarkers, such as C-reactive protein (CRP), procalcitonin (PCT), and ferritin, were significantly elevated in the resolved HBV infection group, as well pro-inflammatory cytokines, including interleukin-6 (IL-6), soluble interleukin-2 receptor (sIL-2R), tumor necrosis factor alpha (TNF- Conclusion: Resolved HBV infection is an independent risk factor for patients with COVID-19. COVID-19 patients with resolved HBV infection are more likely to have enhanced systemic inflammatory responses and worse prognoses than those with non-HBV infection.

Indexed as

COVID-19cytokineimmune dysregulationinflammatory responseresolved HBV infection

Identifiers

PMID42583378
PMCPMC13459760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.